Intravenous gammaglobulin therapy in the management of a patient with idiopathic thrombocytopenic purpura and a warm autoimmune erythrocyte panagglutinin during pregnancy.
Intravenous gammaglobulin (IVIgG) was recently introduced for the treatment of idiopathic thrombocytopenic purpura (ITP). Reported is a previously splenectomized patient who had a severe exacerbation of her ITP during pregnancy and was managed with large doses of IVIgG throughout the second half of her pregnancy. She also had an autoimmune IgG erythrocyte panagglutinin on her red blood cells and in her serum, but only minimal evidence of hemolysis. There was little or no transplacental passage of her autoimmune antibodies since she delivered a normal fetus after 34 weeks of gestation who had a normal platelet count and no evidence of an antierythrocyte antibody. Interestingly, at the time of delivery the mother's serum IgG was dramatically elevated, but the cord serum IgG was normal for the length of gestation, indicating the presence of a dramatic and abnormal difference in IgG between maternal and fetal blood. This raises the possibility that the IVIgG therapy may have actually prevented transplacental passage of the pathological antibodies.
D000328:Adult; D000373:Agglutinins / Q000032:analysis; D001327:Autoimmune Diseases / Q000150:complications; D001792:Blood Platelets / Q000473:pathology; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D005312:Fetal Blood; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D010976:Platelet Count; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000628:therapy*; D011696:Purpura, Thrombocytopenic / Q000097:blood / Q000628:therapy*; D013156:Splenectomy
D000373:Agglutinins; D007074:Immunoglobulin G